Both a biopsy method and a therapeutic procedure in BI-RADS 4A and 4B lesions: Ultrasound-guided vacuumassisted breast biopsy

Abstract

Objective: This study aimed to evaluate outcomes, complications, and follow-up results of ultrasound-guided vacuum-assisted breast biopsy (UG-VABB) in BI-RADS 4 A and B lesions. Material and Methods: Between Agust 2014 to January 2018, fifty BI-RADS 4A and BI-RADS 4B lesions of 41 patients biopsied with 10G vacuum needle by a single radiologist were retrospectively evaluated. Results: All patients were females and mean age of the 41 patients was 50.12 ± 8.63. Of all lesions, 84% was benign, 6% was ADH, 4% was in-situ cancer, and 6% was diagnosed as malign. Follow-up duration after VABB was 0-51 months and mean was 20.92 months. Complications were as vasovagalinduced seizure in 3 patients (7.3%) and intramammary hematoma in 16 patients (39%). Hematoma was diagnosed in 3 patients (7.3%) at the 6 th month follow-up and it was resolved in all patients at the 12 th month follow-up. Higher breast density resulted in higher hematoma rates. There was no relationship between lesion BI-RADS subgroups, lesion size or sample number and hematoma development. During the follow-up, residue lesion in 1 (2.4%) patient and scar tissue in 2 (4.9%) patients was detected. Conclusion: US-guided VABB, with low complication rates and low scar development, is also a therapeutic excision method without remaining residue, which should be primarily preferred in smaller than 2 cm BI-RADS 4A and 4B lesions whose malignancy rates are relatively low. Hematoma, which is the most frequent complication, resorbed entirely in the 12 th month in all patients.

Efficacy and Safety of Vacuum-Assisted Excision for Benign Breast Mass Lesion: A Meta-Analysis

“…Fine-needle aspiration and core needle biopsy cannot examine the whole mass, whereas VAE can perform a full examination of the entire mass. Owing to the advantage that VAE can remove the entire mass region, VAE has recently been widely used for both diagnostic and therapeutic purposes [3][4][5]. In 2002, the US Food and Drug Administration (FDA) approved VAE for the removal of benign lesions.…”

Biópsia a vácuo como ferramenta diagnóstica em lesões ultrassonográficas BI-RADS 4a

“…Segundo o Instituto Nacional do Câncer (INCA), o câncer de mama é o tipo de câncer mais comum entre as mulheres no Brasil, correspondendo a cerca de 30% dos novos casos de câncer diagnosticados a cada ano.Embora os dados específicos sobre o estadiamento 4A não sejam divulgados de forma separada, sabe-se que cerca de 2 a 10% dos casos de câncer de mama são diagnosticados como estágio 4A no momento do diagnóstico, o que corresponde a lesão de baixa suspeita para malignidade, representando a importância de estudos que analisem técnicas diagnósticas para estas lesões. Mais especificamente, tratando da ultrassonografia, as lesões que podem ser classificadas como BI-RADS 4A incluem nódulos sólidos hipoecóicos (isto é, com baixa ecogenicidade) e lesões complexas, tais como cistos com conteúdo sólido ou nódulos com calcificações periféricas(DINÇ ELIBOL et al, 2020).…”